Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 3 of 3 entries
View as:
Phase: N/A
Priority: Normal
Start: 11/03/22
End: 08/18/23
Due: 08/18/24
Phase: N/A
Priority: Normal
Start: 12/31/09
End: 10/31/14
Due: 10/31/15
Phase: N/A
Priority: Normal
Start: 01/31/13
End: 12/31/15
Due: 12/31/16
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Asunercept for the Treatment of Patients With Moderate to Severe COVID-19 Disease | NCT05639192 | Apogenix GmbH | user2@example.com | None | 2022-11-03 | 2023-08-18 | 2024-08-18 | - | - | 2025-07-14 |
| APG101 in Glioblastoma | NCT01071837 | Apogenix GmbH | user2@example.com | None | 2009-12-31 | 2014-10-31 | 2015-10-31 | - | - | 2025-07-14 |
| APG101 in Myelodysplastic Syndrome | NCT01736436 | Apogenix GmbH | user2@example.com | None | 2013-01-31 | 2015-12-31 | 2016-12-31 | - | - | 2025-07-14 |